<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00368654</url>
  </required_header>
  <id_info>
    <org_study_id>200513613</org_study_id>
    <nct_id>NCT00368654</nct_id>
  </id_info>
  <brief_title>Evaluate Whether Combination Therapy With Methotrexate and Raptiva in Psoriasis Patients is Safe and Increases Efficacy</brief_title>
  <official_title>An Open-Label Study to Evaluate Whether a Short-Term Course of Methotrexate in Psoriasis Patients Treated With Efalizumab is Safe and Increases Efficacy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether a short-term course of methotrexate in patients treated with efalizumab
      (Raptiva) increases efficacy. The secondary objectives of this study are 1) to evaluate the
      efficacy of Raptiva in maintaining the clinical improvement induced by short-term treatment
      with combination therapy of Raptiva and methotrexate 2) to evaluate the safety of short-term
      combination therapy of Raptiva and methotrexate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate whether a short-term course of
      methotrexate in patients treated with efalizumab (Raptiva) increases efficacy. The secondary
      objectives of this study are 1) to evaluate the efficacy of Raptiva in maintaining the
      clinical improvement induced by short-term treatment with combination therapy of Raptiva and
      methotrexate 2) to evaluate the safety of short-term combination therapy of Raptiva and
      methotrexate.

      The design of this study is to gain better control of the disease process while reducing
      potential toxicities by beginning treatment with Raptiva and adding methotrexate to those
      patients who do not improve significantly
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PASI -- Psoriasis Area and Severity Index</measure>
    <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
    <description>(PASI) - given by numerical score, the index shows the severity of psoriasis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AE)</measure>
    <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
    <description>measured by whether or not AE was serious</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Monotherapy with Raptiva alone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination therapy with both Raptiva and Methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue Raptiva, discontinue methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continue combination therapy with both Raptiva and Methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Initial dose 5 mg, then 15 mg per week</description>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva</intervention_name>
    <description>Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <other_name>Efalizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe plaque-type psoriasis

          -  A candidate for systemic therapy or phototherapy

          -  Not using prescription systemic therapies for psoriasis prior to starting the study

          -  Not using efalizumab within 3 months prior to starting the study

        We are seeking adults who:

          -  Have moderate to severe plaque-type psoriasis

          -  Are generally healthy

          -  Are not hypersensitive to RaptivaÂ® (efalizumab) or any of its components.

          -  Are not pregnant or lactating women

        You will:

          -  Be interviewed and examined

          -  Have blood drawn

          -  Be injecting the study medication

        Exclusion Criteria:

          -  Hypersensitivity to Raptiva or any of its components

          -  Pregnant or lactating women

          -  History of liver disease or abnormal liver enzymes

          -  History of chronic infection or malignancy

          -  History of significant hematologic abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chai Sue Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Medical Center Department of Dermatology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.ucdmc.ucdavis.edu/dermatology/research/clinical</url>
    <description>University of California-Davis Department of Dermatology Clinical Research</description>
  </link>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>August 24, 2006</study_first_submitted>
  <study_first_submitted_qc>August 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2006</study_first_posted>
  <results_first_submitted>December 11, 2017</results_first_submitted>
  <results_first_submitted_qc>May 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2018</results_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>A-Monotherapy With Raptiva Alone</title>
          <description>Monotherapy with Raptiva alone
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>B-Combination Therapy With Both Raptiva and Methotrexate</title>
          <description>Combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>C-Continue Raptiva, Discontinue Methotrexate</title>
          <description>Continue Raptiva, discontinue methotrexate
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="P4">
          <title>D-Continue Combination Therapy With Both Raptiva and Methotrex</title>
          <description>Continue combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>A-Monotherapy With Raptiva Alone</title>
          <description>Monotherapy with Raptiva alone
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="B2">
          <title>B-Combination Therapy With Both Raptiva and Methotrexate</title>
          <description>Combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="B3">
          <title>C-Continue Raptiva, Discontinue Methotrexate</title>
          <description>Continue Raptiva, discontinue methotrexate
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="B4">
          <title>D-Continue Combination Therapy With Both Raptiva and Methotrex</title>
          <description>Continue combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" spread="NA">data not collected</measurement>
                    <measurement group_id="B2" value="NA" spread="NA">data not collected</measurement>
                    <measurement group_id="B3" value="NA" spread="NA">data not collected</measurement>
                    <measurement group_id="B4" value="NA" spread="NA">data not collected</measurement>
                    <measurement group_id="B5" value="NA" spread="NA">data not collected</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">data not collected</measurement>
                    <measurement group_id="B2" value="NA">data not collected</measurement>
                    <measurement group_id="B3" value="NA">data not collected</measurement>
                    <measurement group_id="B4" value="NA">data not collected</measurement>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">data not collected</measurement>
                    <measurement group_id="B2" value="NA">data not collected</measurement>
                    <measurement group_id="B3" value="NA">data not collected</measurement>
                    <measurement group_id="B4" value="NA">data not collected</measurement>
                    <measurement group_id="B5" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PASI -- Psoriasis Area and Severity Index</title>
        <description>(PASI) - given by numerical score, the index shows the severity of psoriasis.</description>
        <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
        <population>data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>A-Monotherapy With Raptiva Alone</title>
            <description>Monotherapy with Raptiva alone
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>B-Combination Therapy With Both Raptiva and Methotrexate</title>
            <description>Combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>C-Continue Raptiva, Discontinue Methotrexate</title>
            <description>Continue Raptiva, discontinue methotrexate
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>D-Continue Combination Therapy With Both Raptiva and Methotrex</title>
            <description>Continue combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>PASI -- Psoriasis Area and Severity Index</title>
          <description>(PASI) - given by numerical score, the index shows the severity of psoriasis.</description>
          <population>data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events (AE)</title>
        <description>measured by whether or not AE was serious</description>
        <time_frame>16 vs. 36 weeks, depending on study arm</time_frame>
        <population>Data not collected</population>
        <group_list>
          <group group_id="O1">
            <title>A-Monotherapy With Raptiva Alone</title>
            <description>Monotherapy with Raptiva alone
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
          <group group_id="O2">
            <title>B-Combination Therapy With Both Raptiva and Methotrexate</title>
            <description>Combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
          <group group_id="O3">
            <title>C-Continue Raptiva, Discontinue Methotrexate</title>
            <description>Continue Raptiva, discontinue methotrexate
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
          <group group_id="O4">
            <title>D-Continue Combination Therapy With Both Raptiva and Methotrex</title>
            <description>Continue combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (AE)</title>
          <description>measured by whether or not AE was serious</description>
          <population>Data not collected</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>All-Cause Mortality, Serious, and Other [Not Including Serious] Adverse Events were not monitored/assessed</desc>
      <group_list>
        <group group_id="E1">
          <title>A-Monotherapy With Raptiva Alone</title>
          <description>Monotherapy with Raptiva alone
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="E2">
          <title>B-Combination Therapy With Both Raptiva and Methotrexate</title>
          <description>Combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="E3">
          <title>C-Continue Raptiva, Discontinue Methotrexate</title>
          <description>Continue Raptiva, discontinue methotrexate
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
        <group group_id="E4">
          <title>D-Continue Combination Therapy With Both Raptiva and Methotrex</title>
          <description>Continue combination therapy with both Raptiva and Methotrexate
Methotrexate: Initial dose 5 mg, then 15 mg per week
Raptiva: Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chai Sue Lee</name_or_title>
      <organization>Kaiser Permanente (Current), UC Davis (Previous)</organization>
      <email>lam.nguyen@ucdmc.ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

